Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Targeted therapies for CNS tumors

Sébastien Perreault • 25 May 2021
ASCO 2021
Brain Tumor Glioma

Sébastien Perreault, MD, FRCPC, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada, reflects on the use of targeted therapies in central nervous system (CNS) tumors, including targeting of the MAP kinase pathways which are prevalent in this patient population, the use of oral agents as well as addressing how long to continue treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Sébastien Perreault, MD, FRCPC has received an advisory board role and conference support from Bayer, conference support from Eisai, and research support from Novartis.

More from Sébastien Perreault

1:15
Larotrectinib, a TRK inhibitor for patients with solid tumors
Sébastien Perreault • 25 May 2021
3:18
Larotrectinib in adult and pediatric patients with TRK fusion-positive primary CNS tumors
Sébastien Perreault • 25 May 2021
1:19
Biomarker testing and treatment of TRK fusion cancer in pediatric patients
Sébastien Perreault • 25 May 2021

Related Videos

2:19
Clinical advances in brain cancer: AZD1390 and CAR-T cells in glioma
Patrick Wen • 12 Apr 2024
1:52
ACTION: ONC201 in H3 K27M–mutant diffuse midline glioma
Patrick Wen • 12 Apr 2024
1:07
Genomic predictors of adverse events in glioblastoma
Patrick Wen • 12 Apr 2024
2:48
Clinical advances in the management of gliomas
Patrick Wen • 12 Apr 2024
The content of VJOncology is intended for healthcare professionals